Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.099
-0.001 (-0.06%)
Oct 19, 2026, 11:27 AM EDT - Market open
Cardiol Therapeutics Employees
Cardiol Therapeutics had 18 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
18
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,333,133
Market Cap
130.41M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 18 | 0 | - |
| Dec 31, 2024 | 18 | - | - |
| Dec 31, 2018 | 6 | - | - |
| Sep 30, 2018 | 8 | - | - |
| Jun 30, 2018 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Organigram Global | 1,120 |
| Organogenesis Holdings | 854 |
| Lifecore Biomedical | 382 |
| Akebia Therapeutics | 194 |
| ADC Therapeutics | 193 |
| Cumberland Pharmaceuticals | 88 |
| BioAge Labs | 62 |
| Journey Medical | 58 |
CRDL News
- 20 days ago - Tejara Capital Ltd Expands Stake in Cardiol Therapeutics Inc (CRDL) with 1.27 Million Share Purchase - GuruFocus
- 26 days ago - Cardiol Therapeutics Slides: Corporate presentation - Filings
- 26 days ago - Cardiol Therapeutics (CRDL) Advances MAVERIC Phase III Trial, Market Implies High Growth ... - GuruFocus
- 26 days ago - Cardiol Therapeutics achieves enrollment target for Phase III MAVERIC trial - TheFly
- 26 days ago - Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy - PRNewsWire
- 4 weeks ago - Cardiol Therapeutics (CRDL) Raises $7M via Warrants, Extends Runway into 2028 - GuruFocus
- 4 weeks ago - Cardiol Therapeutics Registration statement: Registration filing - Filings
- 4 weeks ago - Cardiol Therapeutics receives over $7M in proceeds from warrant exercise - TheFly